Artelo Biosciences (ARTL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Feb, 2026Opening remarks and agenda
Meeting opened with introductions of board members, legal counsel, auditors, and election inspector.
Agenda included formal business, voting on proposals, and a Q&A session.
Board and executive committee updates
Board Chair and Compensation Committee Chair were present and introduced.
Two current directors, Douglas Blayney, MD, and Connie Matsui, were nominated for re-election as Class II directors.
Shareholder proposals
Election of two Class II directors to serve until the 2028 annual meeting.
Advisory vote on executive compensation ("say on pay").
Ratification of MaloneBailey, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Artelo Biosciences
- Equity line agreement enables up to $50M in funding but poses dilution and market risks.ARTL
Registration filing24 Mar 2026 - Biopharma seeks $10.9M via equity/warrants to fund clinical pipeline amid Nasdaq compliance risks.ARTL
Registration filing24 Mar 2026 - Lead programs show strong clinical progress in cancer anorexia, neuropathy, and anxiety.ARTL
Corporate presentation24 Mar 2026 - Biopharma seeks up to $10.8M via share/warrant offering to fund clinical pipeline, with dilution risk.ARTL
Registration filing23 Mar 2026 - Biopharma seeks $10.8M via stock and warrants to fund clinical pipeline, facing dilution and listing risks.ARTL
Registration filing20 Mar 2026 - Strong clinical advances offset by higher net loss and lower cash reserves in 2025.ARTL
Q4 202524 Feb 2026 - Net loss narrowed, cash runway extends into Q4 2025, and key clinical milestones are expected.ARTL
Q3 20245 Feb 2026 - Promising clinical pipeline in pain, cancer, and mental health, backed by strong IP and leadership.ARTL
Investor presentation30 Jan 2026 - Four clinical milestones expected in 18 months, targeting billion-dollar therapeutic markets.ARTL
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026